Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (281-290 of 539) with videos related to

Pageof 54
Sort By:
Investigative Radiology|November 28, 2021
Repeatability and Reproducibility of ADC Measurements and MRI Signal Intensity Measurements of Bone Marrow in Monoclonal Plasma Cell Disorders: A Prospective Bi-institutional Multiscanner, Multiprotocol StudyMarkus Wennmann, Heidi Thierjung, Fabian Bauer, et al.
Haematologica|July 28, 2011
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapyMark van Duin, Annemiek Broyl, Yvonne de Knegt, et al.
The British Journal of Radiology|March 31, 2023
Test-retest, inter- and intra-rater reproducibility of size measurements of focal bone marrow lesions in MRI in patients with multiple myelomaMarkus Wennmann, Martin Grözinger, Vivienn Weru, et al.
Communications Biology|March 12, 2019
Genome-wide interaction and pathway-based identification of key regulators in multiple myelomaSubhayan Chattopadhyay, Hauke Thomsen, Pankaj Yadav, et al.
Molecular Cancer Therapeutics|December 10, 2020
HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma CellsVianihuini Figueroa-Vazquez, Jonathan Ko, Christian Breunig, et al.
Blood|February 12, 2011
Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)Tilmann Bochtler, Ute Hegenbart, Christiane Heiss, et al.
Journal of Magnetic Resonance Imaging : JMRI|May 11, 2024
Reproducible Radiomics Features from Multi-MRI-Scanner Test-Retest-Study: Influence on Performance and Generalizability of ModelsMarkus Wennmann, Lukas T Rotkopf, Fabian Bauer, et al.
Cancers|September 28, 2023
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE TrialLisa B Leypoldt, Maria Gavriatopoulou, Britta Besemer, et al.
Blood|January 30, 2019
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myelomaAnjan Thakurta, Maria Ortiz, Pedro Blecua, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple MyelomaDavid S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
Pageof 54

Showing results (281-290 of 539) with videos related to

Sort By:
Pageof 54
Investigative Radiology|November 28, 2021
Repeatability and Reproducibility of ADC Measurements and MRI Signal Intensity Measurements of Bone Marrow in Monoclonal Plasma Cell Disorders: A Prospective Bi-institutional Multiscanner, Multiprotocol StudyMarkus Wennmann, Heidi Thierjung, Fabian Bauer, et al.
Haematologica|July 28, 2011
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapyMark van Duin, Annemiek Broyl, Yvonne de Knegt, et al.
The British Journal of Radiology|March 31, 2023
Test-retest, inter- and intra-rater reproducibility of size measurements of focal bone marrow lesions in MRI in patients with multiple myelomaMarkus Wennmann, Martin Grözinger, Vivienn Weru, et al.
Communications Biology|March 12, 2019
Genome-wide interaction and pathway-based identification of key regulators in multiple myelomaSubhayan Chattopadhyay, Hauke Thomsen, Pankaj Yadav, et al.
Molecular Cancer Therapeutics|December 10, 2020
HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma CellsVianihuini Figueroa-Vazquez, Jonathan Ko, Christian Breunig, et al.
Blood|February 12, 2011
Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)Tilmann Bochtler, Ute Hegenbart, Christiane Heiss, et al.
Journal of Magnetic Resonance Imaging : JMRI|May 11, 2024
Reproducible Radiomics Features from Multi-MRI-Scanner Test-Retest-Study: Influence on Performance and Generalizability of ModelsMarkus Wennmann, Lukas T Rotkopf, Fabian Bauer, et al.
Cancers|September 28, 2023
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE TrialLisa B Leypoldt, Maria Gavriatopoulou, Britta Besemer, et al.
Blood|January 30, 2019
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myelomaAnjan Thakurta, Maria Ortiz, Pedro Blecua, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple MyelomaDavid S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
Pageof 54